Metacrine, Inc. (MTCR)

NASDAQ: MTCR · IEX Real-Time Price · USD
0.566
-0.001 (-0.12%)
Mar 28, 2023, 4:00 PM EDT - Market closed
-0.12%
Market Cap 24.81M
Revenue (ttm) n/a
Net Income (ttm) -38.19M
Shares Out 43.83M
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,494
Open 0.575
Previous Close 0.567
Day's Range 0.566 - 0.575
52-Week Range 0.303 - 0.676
Beta -0.77
Analysts Sell
Price Target 0.51 (-9.89%)
Earnings Date May 10, 2023

About MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 16, 2020
Employees 10
Stock Exchange NASDAQ
Ticker Symbol MTCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MTCR stock is "Sell." The 12-month stock price forecast is $0.51, which is a decrease of -9.89% from the latest price.

Price Target
$0.51
(-9.89% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. ...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.

NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Co...

Other symbols: EQ
4 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.

NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Co...

Other symbols: EQ
4 months ago - PRNewsWire

Metacrine Reports Third-Quarter 2022 Results

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, ...

4 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, ECOM, MTCR, MNRL

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

6 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...

Other symbols: EQRCKT
6 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR

NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...

Other symbols: EQSGFY
6 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Metacrine, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - September 8, 2022) - Rigrodsky Law, P.A. is investigating Metacrine, Inc. ("Metacrine") (NASDAQ: MTCR) regarding possible breaches of fiduciary duties and other...

7 months ago - Newsfile Corp

MTCR Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Metacrine Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Metacrine Inc. (NASDAQ: MTCR) and Equillium, Inc. is fair to Metacrine shareholders. Ha...

7 months ago - Business Wire

Equillium to Acquire Metacrine in All-Stock Transaction

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement ...

Other symbols: EQ
7 months ago - Business Wire

Metacrine Reports Second-Quarter 2022 Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, ...

8 months ago - GlobeNewsWire

Metacrine Reports First-Quarter 2022 Results

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, t...

11 months ago - GlobeNewsWire

Metacrine Reports Fourth-Quarter 2021 Results

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases,...

1 year ago - GlobeNewsWire

Metacrine Announces Executive Leadership Changes

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, ...

1 year ago - GlobeNewsWire

Metacrine To Slash Its Workforce By 50%

Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in...

1 year ago - Benzinga

Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan

SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

1 year ago - GlobeNewsWire

Metacrine Announces Resignation of Chief Medical Officer

SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

1 year ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?

Investors need to pay close attention to Metacrine (MTCR) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Metacrine Reports Third-Quarter 2021 Results

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver ...

1 year ago - GlobeNewsWire

Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...

1 year ago - GlobeNewsWire

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

1 year ago - GlobeNewsWire

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

1 year ago - GlobeNewsWire

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...

1 year ago - GlobeNewsWire

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...

1 year ago - GlobeNewsWire

Metacrine to Present at 2021 Canaccord Genuity Growth Conference

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal ...

1 year ago - GlobeNewsWire